Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Post by stockman6767on Nov 21, 2019 12:10pm
153 Views
Post# 30378678

What will the new "Ryplazim partnership" include?

What will the new "Ryplazim partnership" include?I am not that clear on what the new "Ryplazim partnership" would include. I have 3 possibilities in mind, 1) it only includes the rights to what will be included under the current expected FDA approval in H1 - Ryplazim™ for the only current indication for treatment of PLGD, or 2) It will also include all rights to all future developments and indications to be treated by Ryplazim for any indication yet to be developed, or 3) this is but a short form terminology that really includes all future protein therapeutics for all plasma derived therapeutics? Until now my understanding has been 1) but I have never really been clear on this. If in fact it is 1), then there will not be very big dollars on the partnership announcement. Anyone have any clarity on this? 
<< Previous
Bullboard Posts
Next >>